LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 29

Search options

  1. Article ; Online: Nonprofit pharma: solutions to what ails the industry.

    Moos, W H / Kodukula, K

    Current medicinal chemistry

    2011  Volume 18, Issue 22, Page(s) 3437–3440

    Abstract: Nonprofit organizations (NPOs) play an increasingly important role providing solutions to the significant challenges faced today by both large pharmaceutical and smaller biotechnology companies, not to mention academia. NPOs chartered for the public ... ...

    Abstract Nonprofit organizations (NPOs) play an increasingly important role providing solutions to the significant challenges faced today by both large pharmaceutical and smaller biotechnology companies, not to mention academia. NPOs chartered for the public benefit are common in the USA and in selected other parts of the world. SRI International, originally founded as the Stanford Research Institute in 1946, is one of the largest and most successful independent NPOs. To provide a perspective on NPO business models, a number of SRI case studies spanning a broad range of technical and business initiatives will be summarized, including basic and contract research, discovery and development of new drugs and biologics, pharmaceutical and biotech research and development and contract services, technology pivots, company spin-ins and spin-outs, and the creation of new NPOs. How to bridge the National Institute of Health's "Valley of Death" and how to navigate the Food and Drug Administration's "Critical Path" will be discussed. We conclude with lessons learned about collaborations and routes to commercialization, along with food for thought for bioscience companies and outsourcing participants. Throughout, we attempt to explain why the role of NPOs is important to both the scientific and business communities and to patients and caregivers.
    MeSH term(s) Biotechnology/trends ; Drug Industry/trends ; Humans ; Industry/trends ; National Institutes of Health (U.S.) ; Organizations, Nonprofit/trends ; United States ; United States Food and Drug Administration
    Language English
    Publishing date 2011-04-22
    Publishing country United Arab Emirates
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1319315-6
    ISSN 1875-533X ; 0929-8673
    ISSN (online) 1875-533X
    ISSN 0929-8673
    DOI 10.2174/092986711796504763
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4432: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Book: Drug discovery technologies

    Clark, C. R / Moos, W. H

    (Ellis Horwood series in pharmaceutical technology)

    1990  

    Author's details editors, C.R. Clark, W.H. Moos
    Series title Ellis Horwood series in pharmaceutical technology
    MeSH term(s) Drug Design ; Technology, Pharmaceutical
    Language English
    Size xv, 283 p., [4] p. of plates :, ill.
    Publisher E. Horwood ; New York : Halsted Press
    Publishing place Chichester
    Document type Book
    Note Includes index.
    ISBN 9780470216040 ; 0470216042
    Database Catalogue of the US National Library of Medicine (NLM)

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article: Drug development for senile cognitive decline.

    Hershenson, F M / Moos, W H

    Journal of medicinal chemistry

    1986  Volume 29, Issue 7, Page(s) 1125–1130

    MeSH term(s) Aged ; Aging ; Animals ; Cognition Disorders/diagnosis ; Cognition Disorders/drug therapy ; Dementia/diagnosis ; Dementia/drug therapy ; Disease Models, Animal ; Drug Therapy/methods ; Humans ; Research Design
    Language English
    Publishing date 1986-07
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 218133-2
    ISSN 1520-4804 ; 0022-2623
    ISSN (online) 1520-4804
    ISSN 0022-2623
    DOI 10.1021/jm00157a001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 151: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MB 1: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Book: Cognitive disorders

    Thal, Leon J / Moos, W. H / Gamzu, Elkan

    pathophysiology and treatment

    (Neurological disease and therapy ; 11)

    1992  

    Author's details edited by Leon J. Thal, Walter H. Moos, Elkan R. Gamzu
    Series title Neurological disease and therapy ; 11
    MeSH term(s) Cognition Disorders/physiopathology ; Cognition Disorders/therapy
    Language English
    Size ix, 388 p. :, ill.
    Publisher M. Dekker
    Publishing place New York
    Document type Book
    ISBN 9780824786014 ; 0824786017
    Database Catalogue of the US National Library of Medicine (NLM)

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article: Combinatorial discovery process yields antimicrobial peptoids.

    Ng, S / Goodson, B / Ehrhardt, A / Moos, W H / Siani, M / Winter, J

    Bioorganic & medicinal chemistry

    1999  Volume 7, Issue 9, Page(s) 1781–1785

    Abstract: N-alkylated glycine trimers are generically referred to as peptoids. The identification of antimicrobial peptoids from a statistically unbiased diverse combinatorial chemistry library led to the design of the optimization peptoid library that we describe ...

    Abstract N-alkylated glycine trimers are generically referred to as peptoids. The identification of antimicrobial peptoids from a statistically unbiased diverse combinatorial chemistry library led to the design of the optimization peptoid library that we describe in this manuscript. This optimization library was designed using structural information from the most active peptoids in the unbiased library. Screening of the optimization library for antimicrobial activity identified a single pool of peptoids with activity against both Staphylococcus aureus and Escherichia coli. The active peptoids from this pool were active against drug sensitive and drug resistant organisms and represent novel antibacterial compounds.
    MeSH term(s) Anti-Bacterial Agents/chemical synthesis ; Anti-Bacterial Agents/chemistry ; Anti-Bacterial Agents/pharmacology ; Combinatorial Chemistry Techniques ; Escherichia coli/drug effects ; Escherichia coli/growth & development ; Microbial Sensitivity Tests ; Oligopeptides/chemical synthesis ; Oligopeptides/chemistry ; Oligopeptides/pharmacology ; Peptoids ; Protein Conformation ; Staphylococcus aureus/drug effects ; Staphylococcus aureus/growth & development
    Chemical Substances Anti-Bacterial Agents ; Oligopeptides ; Peptoids
    Language English
    Publishing date 1999-10-15
    Publishing country England
    Document type Journal Article
    ZDB-ID 1161284-8
    ISSN 1464-3391 ; 0968-0896
    ISSN (online) 1464-3391
    ISSN 0968-0896
    DOI 10.1016/s0968-0896(99)00132-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3815: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Evaluation in rats of the somnogenic, pyrogenic, and central nervous system depressant effects of muramyl dipeptide.

    Meltzer, L T / Serpa, K A / Moos, W H

    Psychopharmacology

    1989  Volume 99, Issue 1, Page(s) 103–108

    Abstract: Muramyl dipeptide increased sleep during the dark-phase, but not the light-phase of the rats' sleep-awake cycle. This circadian variation may be due to the inability of MDP to increase sleep over the high baseline levels of sleep that occur during the ... ...

    Abstract Muramyl dipeptide increased sleep during the dark-phase, but not the light-phase of the rats' sleep-awake cycle. This circadian variation may be due to the inability of MDP to increase sleep over the high baseline levels of sleep that occur during the light-phase. However, MDP was pyrogenic during the light-phase, indicating it was pharmacologically active. In the dark-phase, MDP was not pyrogenic, but when compared to concurrent vehicle-treated rats, rats treated with MDP did not demonstrate as great a fall in body temperature. At approximately equisomnogenic doses, MDP produced less potentiation of ethanol-induced loss of righting reflex than triazolam, indicating it produces less non-specific central nervous system depressant effects. These data indicate the possibility of a new generation of hypnotic agents derived from muramyl peptides.
    MeSH term(s) Acetylmuramyl-Alanyl-Isoglutamine/pharmacology ; Animals ; Body Temperature/drug effects ; Central Nervous System Depressants/pharmacology ; Dose-Response Relationship, Drug ; Ethanol/pharmacology ; Interleukin-1/physiology ; Male ; Prostaglandins/biosynthesis ; Rats ; Rats, Inbred Strains ; Reflex/drug effects ; Sleep/drug effects ; Triazolam/pharmacology
    Chemical Substances Central Nervous System Depressants ; Interleukin-1 ; Prostaglandins ; Triazolam (1HM943223R) ; Ethanol (3K9958V90M) ; Acetylmuramyl-Alanyl-Isoglutamine (53678-77-6)
    Language English
    Publishing date 1989
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 130601-7
    ISSN 1432-2072 ; 0033-3158
    ISSN (online) 1432-2072
    ISSN 0033-3158
    DOI 10.1007/bf00634462
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui I Zs.240: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Pharmaceutical applications of biotechnology: promise and reality.

    Moos, W H / DiRita, V J / Oxender, D L

    Current opinion in biotechnology

    1993  Volume 4, Issue 6, Page(s) 711–713

    MeSH term(s) Animals ; Biotechnology/trends ; Humans ; Recombinant Proteins/therapeutic use
    Chemical Substances Recombinant Proteins
    Language English
    Publishing date 1993-12
    Publishing country England
    Document type Editorial
    ZDB-ID 1052045-4
    ISSN 1879-0429 ; 0958-1669
    ISSN (online) 1879-0429
    ISSN 0958-1669
    DOI 10.1016/0958-1669(93)90054-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3071: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists.

    Moos, W H / Szotek, D S / Bruns, R F

    Journal of medicinal chemistry

    1985  Volume 28, Issue 10, Page(s) 1383–1384

    MeSH term(s) Adenosine/analogs & derivatives ; Adenosine/chemical synthesis ; Adenosine/metabolism ; Animals ; Kinetics ; Rats ; Receptors, Cell Surface/antagonists & inhibitors ; Receptors, Cell Surface/metabolism ; Receptors, Purinergic ; Structure-Activity Relationship
    Chemical Substances Receptors, Cell Surface ; Receptors, Purinergic ; Adenosine (K72T3FS567)
    Language English
    Publishing date 1985-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 218133-2
    ISSN 1520-4804 ; 0022-2623
    ISSN (online) 1520-4804
    ISSN 0022-2623
    DOI 10.1021/jm00148a001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 151: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MB 1: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Cognition activators.

    Moos, W H / Davis, R E / Schwarz, R D / Gamzu, E R

    Medicinal research reviews

    1988  Volume 8, Issue 3, Page(s) 353–391

    MeSH term(s) Alzheimer Disease/drug therapy ; Animals ; Cognition Disorders/drug therapy ; Disease Models, Animal ; Humans ; Psychotropic Drugs/therapeutic use
    Chemical Substances Psychotropic Drugs
    Language English
    Publishing date 1988-07
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 603210-2
    ISSN 0198-6325
    ISSN 0198-6325
    DOI 10.1002/med.2610080303
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1764: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Therapeutic intervention in dementia.

    Davis, R E / Emmerling, M R / Jaen, J C / Moos, W H / Spiegel, K

    Critical reviews in neurobiology

    1993  Volume 7, Issue 1, Page(s) 41–83

    Abstract: The search for novel therapeutics for human cognitive disorders has intensified. Neurotransmitter replacement therapies represent a short-term hope for treating cognitive dysfunction associated with Alzheimer's disease (AD). AD, however, is clearly a ... ...

    Abstract The search for novel therapeutics for human cognitive disorders has intensified. Neurotransmitter replacement therapies represent a short-term hope for treating cognitive dysfunction associated with Alzheimer's disease (AD). AD, however, is clearly a neurodegenerative disease and is characterized by a loss of synaptic elements. Ultimately, synaptic loss must be halted to alter the disease course. Agents mimicking or modulating the actions of neurotrophic factors may be useful. They may restore lost function and exert anabolic effects on existing neurons, making treated cells less susceptible to neurotoxic insult (i.e., excitotoxicity, oxidative stress, etc.). Intervening in the biogenesis of amyloid plaques and blunting local inflammatory responses may provide the ultimate treatment for AD. The success of any treatment, however, rests on early diagnosis. Early intervention in the neurodegenerative disease process will be required. Without early intervention, the risk of maintaining patients in a premorbid state is high. Therefore, it is likely that no single approach will provide optimal therapy for the AD patient and multifactorial treatment strategies may be required.
    MeSH term(s) Alzheimer Disease/diagnosis ; Alzheimer Disease/etiology ; Animals ; Cognition Disorders/drug therapy ; Dementia/drug therapy ; Disease Models, Animal ; Humans ; Neurotransmitter Agents/therapeutic use
    Chemical Substances Neurotransmitter Agents
    Language English
    Publishing date 1993
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1086045-9
    ISSN 0892-0915
    ISSN 0892-0915
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1992: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top